| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014754009 |
| P356 | DOI | 10.2165/11204910-000000000-00000 |
| P698 | PubMed publication ID | 20481644 |
| P2093 | author name string | James E Frampton | |
| P2860 | cites work | Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin | Q77555487 |
| Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma) | Q94801370 | ||
| Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients | Q28340325 | ||
| Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. | Q34404179 | ||
| Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents | Q34536355 | ||
| Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration | Q34563351 | ||
| Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma | Q34565567 | ||
| Muramyl Tripeptide Phosphatidylethanolamine Encapsulated in Liposomes Stimulates Monocyte Production of Tumor Necrosis Factor and Interleukin-1 In Vitro | Q34574019 | ||
| Osteosarcoma (osteogenic sarcoma). | Q34574274 | ||
| Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases | Q34588395 | ||
| Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma | Q34613462 | ||
| Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer | Q34637891 | ||
| Interleukin-6 induction by a muramyltripeptide derivative in cancer patients | Q34648442 | ||
| Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide | Q34677581 | ||
| In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. | Q34686820 | ||
| Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma | Q34724226 | ||
| Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? | Q34730127 | ||
| Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes | Q34731511 | ||
| Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group | Q34743615 | ||
| Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. | Q34996698 | ||
| Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro | Q35885792 | ||
| Osteosarcoma: current status of immunotherapy and future trends (Review). | Q36390381 | ||
| Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma | Q36512499 | ||
| Nano- or submicron-sized liposomes as carriers for drug delivery | Q36628408 | ||
| Tumour-targeted nanomedicines: principles and practice. | Q36858135 | ||
| Therapy for osteosarcoma: where do we go from here? | Q37255178 | ||
| Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group | Q37439345 | ||
| Novel agents in development for pediatric sarcomas | Q37483347 | ||
| Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37489008 | ||
| Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide | Q40725142 | ||
| Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma | Q40733882 | ||
| Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine | Q41225245 | ||
| Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells | Q41526085 | ||
| Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides | Q41981362 | ||
| Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine | Q44957769 | ||
| Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma | Q45053521 | ||
| Osteosarcoma: the same old drugs or more? | Q46530375 | ||
| Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously | Q46936288 | ||
| Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice | Q48465632 | ||
| Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat | Q53461587 | ||
| Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. | Q54446297 | ||
| Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages | Q54459844 | ||
| Complexities in interpretation of osteosarcoma clinical trial results. | Q55050090 | ||
| Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients | Q68707114 | ||
| Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes | Q69024309 | ||
| Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma | Q69190542 | ||
| Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine | Q69485404 | ||
| Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes | Q70305799 | ||
| The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide | Q70401320 | ||
| Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide | Q71681186 | ||
| Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation | Q71884079 | ||
| Liposome-encapsulated Muramyl Tripeptide Phosphatidylethanolamine for the Treatment of Feline Mammary Adenocarcinoma-A Multicenter Randomized Double-blind Study | Q72032090 | ||
| Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide | Q72052335 | ||
| Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes | Q72256560 | ||
| Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells | Q72366999 | ||
| In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells | Q72487177 | ||
| Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy | Q72705583 | ||
| Osteosarcoma | Q73671887 | ||
| In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells | Q73886615 | ||
| Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance | Q74099963 | ||
| Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma | Q74619547 | ||
| Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial | Q77555196 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 141-153 | |
| P577 | publication date | 2010-06-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Pediatric Drugs | Q15767256 |
| P1476 | title | Mifamurtide: a review of its use in the treatment of osteosarcoma | |
| P478 | volume | 12 |
| Q33889409 | A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep |
| Q38577297 | Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics |
| Q47096040 | Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. |
| Q65556503 | Clinical cancer nanomedicine |
| Q39395402 | Extremophilic proteases as novel and efficient tools in short peptide synthesis |
| Q99629805 | Glycoconjugates via phosphorus ylides |
| Q90481445 | Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy |
| Q28088363 | Immunotherapy for Bone and Soft Tissue Sarcomas |
| Q48192967 | Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals. |
| Q41988197 | Managing sarcoma: where have we come from and where are we going? |
| Q35945493 | Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments |
| Q94397831 | Molecular pathogenesis and therapeutic strategies of human osteosarcoma |
| Q64072797 | Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy |
| Q38151549 | Nanooncology: the future of cancer diagnosis and therapy |
| Q34230175 | Nanopharmaceuticals (part 1): products on the market |
| Q37601242 | Nanotherapeutics in the EU: an overview on current state and future directions |
| Q38690773 | Pattern recognition receptors: immune targets to enhance cancer immunotherapy |
| Q89287784 | Pediatric Cancer Immunotherapy: Opportunities and Challenges |
| Q64123045 | Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs |
| Q33887987 | Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment |
| Q33887982 | Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment |
| Q26750631 | Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma |
| Q45070056 | Synthesis of isotopically labeled versions of L-MTP-PE (mifamurtide) and MDP. |
| Q89699693 | The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis |
Search more.